At the upcoming ISCTM 2024 Autumn Conference, our team will present a poster titled: EEG-based, machine learning biomarker to predict treatment response from SSRI antidepressant treatment and TMS treatment of MDD patients. We are excited to showcase our innovative biomarker solutions and how they can benefit your clinical research/practice or drug development programs. We look forward to meeting you at ISCTM on September 12-13 in San Diego. #ISCTM2024 #mentalhealth #biomarker #TMS
Neumarker Inc.
Mental Health Care
Palo Alto, California 175 followers
AI-empowered brain biomarkers for precision neuromedicine
About us
CNS disorders are often treated ineffectively by trial-and-error, causing prolonged patient distress and high healthcare costs. Neumarker aims to transform the treatment of CNS disorders through its cutting-edge brain biomarker discovery platform, powered by AI. By identifying predictive brain biomarkers, we can personalize treatment for each patient and accelerate drug development by efficient clinical trials. Neumarker is committed to advancing precision neuromedicine through collaborations with drug developers, clinicians and academic researchers.
- Website
-
http://neumarker.ai/
External link for Neumarker Inc.
- Industry
- Mental Health Care
- Company size
- 11-50 employees
- Headquarters
- Palo Alto, California
- Type
- Privately Held
- Founded
- 2022
- Specialties
- Data analytics, brain biomarkers, CNS disorders, precision medicine and mental health
Locations
-
Primary
Get directions
Palo Alto, California 94303, US
Employees at Neumarker Inc.
Updates
-
The ASCP meeting is only a week away, Neumarker will be presenting a talk and poster in the following sessions, Presentation: An EEG-Based, Machine Learning Biomarker to Identify Responsive vs. Non-responsive Subjects in an MDD Clinical Trial: Initial Validation Data from the EMBARC Study Database. 5:37-5:56pm on Thursday May 30th, Salon 2 Poster W58: An EEG-Based, Machine Learning Biomarker to Identify Responsive Vs. Non-Responsive Subjects in an MDD Clinical Trial: Early Validation Data from the EMBARC and ROTTCO Studies. 11:15am-1:00pm on Wednesday May 29, Salon 4 This is a great opportunity to learn more about our innovative biomarker solutions and how they can benefit your clinical reseach/practice or drug development programs. We hope to have you joining us and engage in insightful discussions. Neumarker Inc., American Society of Clinical Psychopharmacology
-
-
Thank Dana Foundation for organizing the Brain Awareness Week. It is the best time to learn more about our brains with a deeper understanding of brain biology and AI-powered analytics tools. #brainAwarenessWeek #mentalheath #biomarkerdiscovery
It’s officially Brain Awareness Week! 🧠 Join us in celebrating the global campaign to foster public enthusiasm and support for brain science. Brain Awareness Week events are happening all over the world, so be sure to follow along using #BrainAwarenessWeek and #BrainWeek! Learn more at https://lnkd.in/e2mBKEfN.
-
-
At the ISCTM 20th annual scientific meeting, our team has presented a poster titled: An EEG-based, Machine Learning Biomarker to Identify Responsive vs. Non-responsive Subjects in an MDD Clinical Trial: Initial Validation Data from the EMBARC Study Database. Please reach out to us, Michael Detke, MD, PhD, Ken Wang and Ruoping Chen, with any questions or discussions. #ISCTM #mentalheath #biomarkers #clinicaltrials